BOOZ ALLEN HAMILTON INC
Federal contract award, Booz Allen Hamilton, $5,638,828
Key CONT_AWD_75F40119F19001_7524_HHSF223201510027B_7524. First seen by this system September 5, 2026 through the historical sweep, new to the watchlist, public 614 days before this system saw it. One version on record.
Cite this row
ac0f864e6514f29a826587f0e1a3d1806c598da59bc6c8edc9d2003a836b9a63The source record can change after this date; the key, hash and retrieval time name exactly the response this system stored. See license and citation.
Versions
| Version | Amount | Change | Occurred | Published | Retrieved | How it arrived | Content hash |
|---|---|---|---|---|---|---|---|
| 1 current | $5,638,828 | first version | January 8, 2019 | December 30, 2024 | 2026-09-05T00:52:47Z | historical sweep | ac0f864e6514 |
Archived copy
https://web.archive.org/web/20260923011431/https://www.usaspending.gov/award/CONT_AWD_75F40119F19001_7524_HHSF223201510027B_7524 captured by this system, September 23, 2026
What the amount is made of
9 recorded actions, so the amount is the award's current total across all of them. 8 of them obligated money. Measured 2026-10-16, when USAspending reported a total obligation of $5,638,828.
| Action date | Modification | Type | Obligated | Description as recorded |
|---|---|---|---|---|
| December 30, 2024 | P00008 | CLOSE OUT | −$8,536 | THIS CONTRACT WILL INVOLVE DEVELOPING A LANDSCAPE ASSESSMENT OF EVIDENTIARY STANDARDS AND DEVELOPING EVIDENTIARY STANDARDS FOR THE USE OF PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILAR DRUG DEVELOPMENT. -THE PURPOSE OF THIS MODIFICATION IS TO DE-OBLIGATE |
| February 10, 2023 | P00007 | OTHER ADMINISTRATIVE ACTION | no money | THIS CONTRACT WILL INVOLVE DEVELOPING A LANDSCAPE ASSESSMENT OF EVIDENTIARY STANDARDS AND DEVELOPING EVIDENTIARY STANDARDS FOR THE USE OF PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILAR DRUG DEVELOPMENT. |
| August 23, 2021 | P00006 | SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | +$1,534,658 | THIS CONTRACT WILL INVOLVE DEVELOPING A LANDSCAPE ASSESSMENT OF EVIDENTIARY STANDARDS AND DEVELOPING EVIDENTIARY STANDARDS FOR THE USE OF PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILAR DRUG DEVELOPMENT. |
| February 22, 2021 | P00005 | SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | +$1,701,713 | THIS CONTRACT WILL INVOLVE DEVELOPING A LANDSCAPE ASSESSMENT OF EVIDENTIARY STANDARDS AND DEVELOPING EVIDENTIARY STANDARDS FOR THE USE OF PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILAR DRUG DEVELOPMENT. |
| April 8, 2020 | P00004 | OTHER ADMINISTRATIVE ACTION | +$330,989 | THIS CONTRACT WILL INVOLVE DEVELOPING A LANDSCAPE ASSESSMENT OF EVIDENTIARY STANDARDS AND DEVELOPING EVIDENTIARY STANDARDS FOR THE USE OF PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILAR DRUG DEVELOPMENT. |
| February 24, 2020 | P00003 | OTHER ADMINISTRATIVE ACTION | +$668,064 | THIS CONTRACT WILL INVOLVE DEVELOPING A LANDSCAPE ASSESSMENT OF EVIDENTIARY STANDARDS AND DEVELOPING EVIDENTIARY STANDARDS FOR THE USE OF PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILAR DRUG DEVELOPMENT. |
| January 29, 2020 | P00002 | OTHER ADMINISTRATIVE ACTION | +$1,500 | THIS CONTRACT WILL INVOLVE DEVELOPING A LANDSCAPE ASSESSMENT OF EVIDENTIARY STANDARDS AND DEVELOPING EVIDENTIARY STANDARDS FOR THE USE OF PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILAR DRUG DEVELOPMENT. THE PURPOSE OF MODIFICATION P0001 IS TO ADD SUPPO |
| May 9, 2019 | P00001 | SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | +$278,016 | THIS CONTRACT WILL INVOLVE DEVELOPING A LANDSCAPE ASSESSMENT OF EVIDENTIARY STANDARDS AND DEVELOPING EVIDENTIARY STANDARDS FOR THE USE OF PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILAR DRUG DEVELOPMENT. THE PURPOSE OF MODIFICATION P0001 IS TO ADD SUPPORT STAFF. THE ORDER AND FUNDED AMOUNT ARE INCREASED BY $278,016.00, FROM $1,132,424.18 TO $1,410,440.18. THE PERFORMANCE PERIOD, JANUARY 14, 2019 THROUGH MARCH 29, 2021, REMAINS UNCHANGED. ALL OTHER TERMS AND CONDITIONS REMAIN THE SAME. |
| January 8, 2019 | base | not on file | +$1,132,424 | THIS CONTRACT WILL INVOLVE DEVELOPING A LANDSCAPE ASSESSMENT OF EVIDENTIARY STANDARDS AND DEVELOPING EVIDENTIARY STANDARDS FOR THE USE OF PHARMACODYNAMIC BIOMARKERS FOR BIOSIMILAR DRUG DEVELOPMENT. |
Last refreshed November 4, 2026 at 2:31 PM UTC.